Skip to main
ACIU

AC Immune (ACIU) Stock Forecast & Price Target

AC Immune (ACIU) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AC Immune is a clinical stage biopharmaceutical company that specializes in Precision Medicine for neurodegenerative diseases, with a focus on discovering and developing therapies targeting misfolded proteins. The company has a diverse pipeline with promising programs, such as ACI-35.030 and ACI-7104.056, which have a 35% and 25% probability of success, respectively. With a strong financial position and upcoming milestone payments, AC Immune is well-positioned for future growth and potential success in the neurodegenerative disease market.

Bears say

AC Immune is a clinical-stage biopharmaceutical company that focuses on developing precision medicine for neurodegenerative diseases, with a significant focus on targeting misfolded proteins. While the company has multiple programs in its pipeline, including promising data for its ACI-24 vaccine and positive results from its PD program, there is no guarantee that these will translate into successful treatments. Additionally, the company's financials may be negatively affected by the high costs of clinical trials and the potential for setbacks or delays in the development process.

AC Immune (ACIU) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AC Immune (ACIU) Forecast

Analysts have given AC Immune (ACIU) a Strong Buy based on their latest research and market trends.

According to 1 analysts, AC Immune (ACIU) has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AC Immune (ACIU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.